Atom Bioscience Enrolling Patients in US as Part of a Global Phase 2b/3 Clinical Trial of a New Investigational Treatment for Chronic Gout
April 24 2024 - 5:30AM
Business Wire
Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co.,
Ltd.), a clinical stage biotechnology company developing new
treatments for inflammatory and metabolic diseases, has begun
enrolling patients in the US for in a Phase 2b/3 clinical trial of
ABP-671, a novel investigational orally administered URAT1
inhibitor, for the treatment of chronic gout. Currently 36 sites
have been identified in 17 states.
The multicenter, randomized, double-blind trial will enroll 580
patients worldwide. For locations of U.S. trial sites and contacts
visit clinicaltrials.gov; (NCT05818085). Part 1 of the trial will
evaluate the safety and efficacy of ABP-671 at different doses and
regimens compared with either placebo or allopurinol, the current
standard of care for management of gout in the U.S. Part 2 of the
study will compare dosing regimens of ABP-671 selected from Part 1
with placebo in patients not enrolled in Part 1.
Gout is one of the most common types of inflammatory arthritis.
It is caused by long-term hyperuricemia, an excessive concentration
of serum uric acid (sUA) greater than 7 mg/dL (420 μmol/L). Gout
seriously affects people's quality of life and can increase the
probability of sudden cardiac death. Existing drugs for treating
chronic gout have poor efficacy and pose serious safety issues,
such as leading to kidney failure, sudden cardiac death, or severe
liver toxicity.
About Atom Bioscience
Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co.
Ltd.) is a fast-growing innovative drug company, focused on
development of best-in-class small molecule therapeutics for
treatment of inflammatory and metabolic diseases. The company’s
lead product, ABP-671, is in clinical development for treatment of
chronic gout. Another small molecule ABP-745 has shown significant
efficacy and good safety in animal models of anti-inflammation, and
is in a phase 1 clinical trial, For more information, please visit:
https://www.atombp.com or atombp.us.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240424464448/en/
For more clinical trial information contact:
https://studykik.com/study-page/gout-16533?utm_source=Opus&utm_medium=Digital
Media Contact: Daniel Eramian Opus Biotech Communications
http://opusbiotech.com/ 425-306-8716
Business Development Contact: Roy J. Wu, MBA Sr. Vice
President, Business Development Atom Bioscience and Pharmaceutical
Co., Ltd Email: roy.wu@atombp.com